Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis.
about
Class IIb HDAC6 regulates endothelial cell migration and angiogenesis by deacetylation of cortactinEpigenetic associations in relation to cardiovascular prevention and therapeuticsTargeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implicationsEpigenetic regulation of endothelial-cell-mediated vascular repairSynergistic induction of apoptosis by HMG-CoA reductase inhibitor and histone deacetylases inhibitor in HeLa cellsRole of histone acetylation in the stimulatory effect of valproic acid on vascular endothelial tissue-type plasminogen activator expression17-β Oestradiol prevents cardiovascular dysfunction in post-menopausal metabolic syndrome by affecting SIRT1/AMPK/H3 acetylationDown-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2HDAC inhibition decreases the expression of EGFR in colorectal cancer cells.Hormone-dependent expression of a steroidogenic acute regulatory protein natural antisense transcript in MA-10 mouse tumor Leydig cellsRole of histone deacetylation in cell-specific expression of endothelial nitric-oxide synthase.Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies.Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.Histone deacetylase 3 antagonizes aspirin-stimulated endothelial nitric oxide production by reversing aspirin-induced lysine acetylation of endothelial nitric oxide synthase.Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanismEpigenetic mechanisms in diabetic vascular complications.CpG signalling, H2A.Z/H3 acetylation and microRNA-mediated deferred self-attenuation orchestrate foetal NOS3 expression.Transcriptional regulation of endothelial arginase 2 by histone deacetylase 2S-nitrosylation in the regulation of gene transcriptionRole of nitric oxide in placental vascular development and function.Nonhistone protein acetylation as cancer therapy targets.Rapid optimization of drug combinations for the optimal angiostatic treatment of cancerTargeting Histone Deacetylases in Diseases: Where Are We?Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, by down-regulating EGFR expression.Differential effects of histone deacetylase inhibitors in tumor and normal cells-what is the toxicological relevance?On the epigenetics of vascular regulation and diseaseComposition, structure and absorption of milk lipids: a source of energy, fat-soluble nutrients and bioactive molecules.Histone deacetylase activity is essential for the expression of HoxA9 and for endothelial commitment of progenitor cellsRoles of nitric oxide and asymmetric dimethylarginine in pregnancy and fetal programming.Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenograftsDevelopment of histone deacetylase inhibitors for cancer treatment.The impact of patient co-morbidities on the regenerative capacity of cardiac explant-derived stem cells.Nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) expression is increased by the histone deacetylase inhibitor trichostatin ATrichostatin A, a histone deacetylase inhibitor suppresses NADPH Oxidase 4-Derived Redox Signalling and AngiogenesisEpigenetics in atherosclerosis and inflammation.Genetics, epigenetics and pharmaco-(epi)genomics in angiogenesisTargeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on?Targeting tumor angiogenesis with histone deacetylase inhibitors.Hyaluronic acid promotes angiogenesis by inducing RHAMM-TGFβ receptor interaction via CD44-PKCδ.Pharmaco-epigenomics: discovering therapeutic approaches and biomarkers for cancer therapy.
P2860
Q24322940-436054FF-FF87-4CCD-A4B0-83DE3585B99EQ26771428-74217711-9627-4BD2-B4AB-63C2DB54B4A6Q26853394-07988633-A1B2-415B-96F9-20CC85868661Q28085420-A9868B0D-D0D6-4507-B590-94C59104A3E0Q28383033-05FD2944-AD85-4F84-AD9F-359C56645355Q28480965-A1D35CB1-EB32-4022-9877-965B17C1C1D8Q28582839-F4ED0CF0-EC8E-499F-B9EF-4EB66168E383Q33813030-0FC9EA57-9F5F-473B-9B3B-40827E0FE5E5Q33862612-02E55CB6-CBF7-432A-AA7F-8788F27E54ACQ33988546-05A26495-F026-4E26-B706-F03023D761CCQ34131621-9AFCB2EF-FBC6-4E1F-AB1A-38E3B2F34E01Q34399444-A1AE0B3F-53AB-457A-A330-0B191A351F64Q34488424-8C2BCF7E-C9ED-446F-BD6C-423D4EBE65E9Q34514079-A7134F3B-3746-4EB2-A716-12A81D88940AQ34839640-2A076D2B-174A-4CB8-BB40-82DCDEEAA29DQ34986508-AB5D85AB-4191-4BC3-9A27-35F866301E89Q35099660-1B3C2D1D-A004-4153-811E-2B66871E1A84Q35228980-212E0824-85A1-44A7-B15D-2E69E217390DQ35492444-50390260-C38B-4FF0-9A69-AABFA0DEDA8FQ35555933-E98C9C45-BD00-4288-AFCF-3447C1F6EC41Q35739676-73333470-A404-476C-BAE0-70A7BF252E08Q35757208-D2E5AC97-E486-4CF0-AA4B-4E3CDF20F1D3Q35821728-F7788266-F088-4FC1-8F6F-E475301655A2Q35911749-0FB0C775-1C87-41C8-B11C-8B2CBDFA0038Q36179533-94A6A9F0-8E22-4367-B251-9D1BA3004B93Q36222404-6AFE5555-5D4A-4447-AA2E-CE6270BABDF1Q36364942-41908A02-7B80-49A4-9172-C0861F88137EQ36403748-D535E93A-B4B3-440A-9E91-6A7EACADE188Q36432504-7C6E2DA0-E747-4953-BD84-ADA331525AA1Q36528232-C471663F-A65B-4234-BF29-1866439816D5Q36788512-1AEF66E4-7B19-4437-9CC1-146EF1381E87Q36937573-F4ECADCC-834F-4B62-B341-4546628C4E63Q36981029-EE65F6E1-09FB-499E-9043-1D0C258ED72EQ37251585-E1463935-7F22-4C70-A55B-7F604428D93EQ37310578-E0BB4AAF-6DB8-4DD5-A95F-FAF94111D35CQ37310665-120E3D63-EEF8-47CD-91C2-226C2F151980Q37317209-217BA621-752C-4F5F-B1EB-C4C34941A9CBQ37359115-05D17B8D-CE8E-4F2D-900E-839541962397Q37461694-459B560D-5777-41BD-A016-A2D683C82A53Q37730440-AF86653F-9855-4170-A5F8-0BCE096476B9
P2860
Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Inhibitors of histone deacetyl ...... sorelaxation and angiogenesis.
@en
type
label
Inhibitors of histone deacetyl ...... sorelaxation and angiogenesis.
@en
prefLabel
Inhibitors of histone deacetyl ...... sorelaxation and angiogenesis.
@en
P2093
P50
P1433
P1476
Inhibitors of histone deacetyl ...... sorelaxation and angiogenesis.
@en
P2093
Beate Fisslthaler
Lothar Rössig
Ulrich Förstermann
P304
P356
10.1161/01.RES.0000037983.07158.B1
P577
2002-11-01T00:00:00Z